SOURCE Neuronascent, Inc.
CLARKSVILLE, Md., May 25 /PRNewswire/ -- Neuronascent, Inc. (http://www.neuronascent.com ) announced today the license of animal cells to Lifeline Cell Technology, LLC, a wholly owned subsidiary of International Stem Cell Corporation (OTC Bulletin Board: ISCO) (http://www.internationalstemcell.com). The worldwide exclusive license covers the marketing, sale and distribution of adult Arctic ground squirrel(AGS) neural stem cells for research use and provides Neuronascent with license fees and royalty income.
The Arctic ground squirrel is the only known mammal capable of lowering its body temperature to below freezing during hibernation. Scientists believe that this tolerance makes AGS cells a unique clinically-relevant model for the study of cerebral ischemia. Dr. Kelly Drew, a collaborator from the University of Alaska-Fairbanks and the Institute for Arctic Biology, summed it up by saying, "Neuronascent has captured tolerance to cerebral ischemia in a neural stem cell line derived from Arctic ground squirrels. This unique extremophile can now be explored by scientists throughout the world."
"Neuronascent is excited to partner with Lifeline Cell Technology in the commercialization of this unique and useful product," said Judith Kelleher-Andersson, Ph.D., President and Chief Scientific Officer of Neuronascent. Dr. Kelleher-Andersson went on to say, "We hope this agreement provides for the distribution of a new research tool for identifying novel therapeutic targets and for animal transplantation research."
Founded in 2004 by Dr. Kelleher-Andersson, Neuronascent, Inc. is a small-molecule drug discovery company developing novel therapeutics based on the science of neurogenesis. Neuronascent's scientists aim to enhance neurogenesis to promote greater numbers of mature neurons that will subsequently promote cognitive improvement in patients with Alzheimer's disease, stroke or depression. Neuronascent has laboratories in Rockville and Walkersville, Maryland.
International Stem Cell Corporation (ISCO) is a biotechnology company focused on developing therapeutic and research products through its subsidiary, Lifeline Cell Technology.
For more information contact: kmattis@neuronascent.com
Safe Harbor Statement
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward- looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations.
SOURCE Neuronascent, Inc.
|
